Take a trial of UK to unlock this pageFind out more
Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value

Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 TTM 2014E 2015E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 13th Aug, paid: 15th Sep more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ +10.9%

FINANCIAL BRIEF: For the six months ended 30 June 2014, AstraZeneca plc revenues increased 2% to $12.87B. Net income decreased 29% to $1.3B. Revenues reflect United States segment increase from $2.25B to $4.95B, Western Europe segment increase from $1.55B to $3.28B. Dividend per share remained flat at $0.90. Basic Earnings per Share excluding Extraordinary Items decreased from $1.47 to $1.03. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score
B-
B-

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Jun '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2014
31st Dec 2015

Price Target: $73.4 (+5.81% above Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: -3.1% ($) ($) ($) ($) ($) ($)
Consensus Estimate
1m Change
3m Change
31 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 5 3 13 5 6

Named Brokers and Analysts
Jefferies & Company, Inc. Jeffrey Holford , Credit Suisse Matthew Weston , SEB Equities Lars Hevreng , Leerink Partners LLC Seamus Fernandez , Sanford Bernstein Tim Anderson , Danske Markets Martin Parkhøi Mattias Haggblom Thomas Bowers , Seymour Pierce , Panmure Gordon Savvas Neophytou , Redeye , Natixis Philippe Lanone , Collins Stewart & Co , Mirabaud Securities Nicholas Turner , Swedbank Markets Johan Unnerus , Nordea Markets Erik Hultgård , Davy , CA Cheuvreux , Macquarie Research , Societe Generale , Handelsbanken Capital Markets Peter Sehested , WestLB Equity Markets , Pareto Securities AS Yilmaz Mahshid , Berenberg Alistair Campbell , DZ Bank , Helvea SA Odile Rundquist , Kepler Cheuvreux Fabian Wenner , Charles Stanley Rae Ellingham , Shore Capital Stockbrokers Brian White , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Matrix Corporate Capital LLP , Liberum Naresh Chouhan , and 1 unnamed other

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca’s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In January 2014, Probiodrug AG transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. In February 2014, Bristol-Myers Squibb Co completed the sale of its global diabetes business to AstraZeneca.

Directors: Pascal Soriot (CEO) 55, Marc Dunoyer (CFO) 61, Ruud Dobber (EVP) , Caroline Hempstead (EVP) , Paul Hudson (EVP) , Bahija Jallal (EVP) , Mark Mallon (EVP) , Briggs Morrison (EVP) , Menelas Pangalos (EVP) , David Smith (EVP) , Leif Johansson (NEC) 63, John Varley (NED) 58, Genevieve Berger (NED) 59, Ann Cairns (NED) 57, Marcus Wallenberg (NED) 58,

No. of Employees: 51,500 No. of Shareholders: 103,411


Last Annual December 31st, 2013
Last Interim June 30th, 2014
Shares in Issue 1,262,751,186
Free Float 1.26bn (99.8%)
ISIN GB0009895292

Address 2 Kingdom Street Paddington, LONDON, W2 6BD, United Kingdom
Web http://www.astrazeneca.com/
Phone +44 20 76048000
Contact Karl Hard (IR Contact Officer)
Auditors KPMG Audit PLC

AZN Share Price Performance AZN Quote
4327.5p
-7.0  -0.2%
Traded 4:36pm · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events
Thursday 6th November, 2014
Q3 2014 AstraZeneca PLC Earnings Release
Thursday 6th November, 2014
Q3 2014 AstraZeneca PLC Earnings Call
Tuesday 18th November, 2014
AstraZeneca PLC Investor Day
Thursday 5th February, 2015
Full Year 2014 AstraZeneca PLC Earnings Release
Friday 24th April, 2015 (estimate)
AstraZeneca PLC Annual Shareholders Meeting

Recent ↓
Sunday 28th September, 2014
AstraZeneca PLC European Society for Medical Oncology (ESMO) 2014 Analysts and Investors Briefing
Tuesday 23rd September, 2014
AstraZeneca PLC at EBD Group BioPharm America
Wednesday 13th August, 2014
Dividend For AZN.L
Wednesday 13th August, 2014
Dividend For AZN
Wednesday 13th August, 2014
Dividend For AZN.BA
Thursday 31st July, 2014
Q2 2014 AstraZeneca PLC Earnings Release
Thursday 31st July, 2014
Q2 2014 AstraZeneca PLC Earnings Call
Thursday 19th June, 2014
AstraZeneca PLC at Citi European Healthcare Conference
Tuesday 3rd June, 2014
AstraZeneca PLC at Jefferies Global Healthcare Conference
Monday 2nd June, 2014
AstraZeneca PLC ASCO Analyst Briefing


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.


Should you buy AZN

Access AZN Analytics Now!

FREE TRIAL or TAKE THE TOUR